SCHEMBL18627939

SCHEMBL18627939

CCC1C(=O)NCCN1c1ncc(-c2cccc(Nc3nccc(C)n3)c2)o1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 13/20 0.47
▸ MAPK1 P28482 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ GALR3 O60755 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ STAT3 P40763 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ ABL1 P00519 2/20 0.36
▸ BCR P11274 2/20 0.36
▸ CDK1 P06493 2/20 0.35
▸ CDK2 P24941 2/20 0.35
▸ SMG1 Q96Q15 2/20 0.35
▸ PRKCQ Q04759 1/20 0.34
▸ BRD4 O60885 1/20 0.33
▸ CDK9 P50750 1/20 0.33
▸ CDC7 O00311 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18627954 0.91 SYK (0.45) SYKABL1BCRCDK1CDK2
SCHEMBL18627916 0.90 SYK (0.43) SYKMAPK1MEN1NPC1GALR3
SCHEMBL18627901 0.89 SYK (0.49) SYKABL1BCRCDK1CDK2
SCHEMBL18627914 0.89 SYK (0.49) SYKABL1BCRCDK1CDK2
SCHEMBL18627956 0.89 SYK (0.49) SYKABL1BCRCDK1CDK2
SCHEMBL18627958 0.89 SYK (0.47) SYK
SCHEMBL18627951 0.87 SYK (0.47) SYKABL1BCRCDK1CDK2
SCHEMBL18627908 0.87 SYK (0.47) SYKABL1BCRCDK1CDK2
SCHEMBL18627910 0.87 SYK (0.47) SYKABL1BCRCDK1CDK2
SCHEMBL18640240 0.84 ROCK2 (0.42) SYKCDK1CDK2SMG1BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3350176-B1 NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK AB SCIENCE (FR) 2021-04-28 — — EP claimed
US-10392373-B2 Oxazole derivatives that inhibit Syk AB SCIENCE (FR) 2019-08-27 — — US claimed
US-20190055230-A1 NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK AB SCIENCE (FR) 2019-02-21 — — US claimed
EP-3144307-A1 NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK AB Science (FR) 2017-03-22 — — EP claimed
EP-3350176-B1 NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK AB SCIENCE (FR) 2021-04-28 — — EP disclosed
US-10392373-B2 Oxazole derivatives that inhibit Syk AB SCIENCE (FR) 2019-08-27 — — US disclosed
US-10392373-B2 Oxazole derivatives that inhibit Syk AB SCIENCE (FR) 2019-08-27 — — US disclosed
US-20190055230-A1 NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK AB SCIENCE (FR) 2019-02-21 — — US disclosed
US-20190055230-A1 NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK AB SCIENCE (FR) 2019-02-21 — — US disclosed
EP-3350176-A1 NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK AB Science (FR) 2018-07-25 — — EP disclosed
WO-2017046302-A1 NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK AB SCIENCE (FR) 2017-03-23 — — WO disclosed
EP-3144307-A1 NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK AB Science (FR) 2017-03-22 — — EP disclosed
EP-3144307-A1 NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK AB Science (FR) 2017-03-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190055230-A1 NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK SYK, BTK, LCK SYK 1/4885MAPK1 234/4885MEN1 4461/4885
US-10392373-B2 Oxazole derivatives that inhibit Syk SYK, BTK, LCK SYK 1/4885MAPK1 217/4885MEN1 4383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback